LINC00511 and neoplasm: Upon tumor formation, mice were randomly assigned to one of four treatment groups: control, AMG-510 monotherapy (p.o., 30 mg/kg, QD), RASON-ASO monotherapy (i.p., 50 nmol, QD), and the combination therapy with AMG-510 and RASON-ASO.